Sleep Disorders Market Analysis 2008-2018

Table of Contents

1 Executive Summary: Pharmaceutical Treatment of Sleep Disorders 2008-2018

• 1.1 Current Prospects of Sleep Disorders Market
  • 1.1.1 Market Growth Estimate
  • 1.1.2 Generic Pharmaceutical Market
  • 1.1.3 Market Expansion
  • 1.1.4 Market Demand for Short Elimination Half-Life
  • 1.1.5 Medications Targeting M1 and M2 Receptors
  • 1.1.6 Medications Targeting 5HT2A Receptor Receptors
  • 1.1.7 Product Line Extension Activities
  • 1.1.8 Effect of Direct-To-Consumer Advertising (DTCA)
  • 1.1.9 Safety Measures for Online Consumers
• 1.2 Aim, Scope, and Format Of This Report

2 Introduction to Sleep Disorders and their Pharmaceutical Treatment

• 2.1 Introduction to Sleep Disorders
• 2.2 Overview of Chapter
• 2.3 Introduction to Insomnia
• 2.4 Discovery of Barbiturates
• 2.5 Market Entry for Non-Barbiturates
• 2.6 Arrival of Benzodiazepines
• 2.7 Non-benzodiazepines the Revolutionary Compound
  • 2.7.1 Prescription Medicines and OTCs
• 2.8 Pharmacodynamics of Hypnotics
• 2.9 Introducing New Scope for Insomnia
• 2.10 Many Forms of Sleep Disturbances
• 2.10.1 Sleep Deprivation
• 2.11 Shift Workers Sleep Disorder (SWSD)
  • 2.11.1 Melatonin
  • 2.11.2 Valerian
• 2.12 Treatment for insomnia in Depression
• 2.13 Restless Legs Syndrome
  • 2.13.1 Off-label Prescription for Restless Legs Syndrome
• 2.14 Other Medical Conditions
• 2.15 Narcolepsy
  • 2.15.1 Xyrem for Cataplexy
  • 2.15.2 Orphan Disease Status
  • 2.15.3 Other Medications for Cataplexy
• 2.16 Obstructive Sleep Apnea / Hypopnea Syndrome (OSAHS)
• 2.17 Insomnia - A Common Disease
• 2.18 Patient Identification Rate

3 Analysis of Current Market for Insomnia

• 3.1 Market Share for World Insomnia Market
• 3.2 Market Dominance Continues for Ambien
• 3.3 Lunesta as Ambien' s Contender
• 3.4 Sonata Continues to Form Niche Market
• 3.5 Imovane / Amoban Go Down in Insomnia Market
• 3.6 Benzodiazepines Survived as Low Priced Sleep Aid
  • 3.6.1 Lendormin (brotizolam)
  • 3.6.2 Halcion (triazolam)
  • 3.6.3 Noctamid (Lormetazepam)
  • 3.6.4 Doral (quazepam)
  • 3.6.5 Dalmane (flurazepam)
  • 3.6.6 Rohypnol (flunitrazepam)
  • 3.6.7 Restoril (temazepam)
  • 3.6.8 Eurodin or ProSom (estazolam)
  • 3.6.9 Rhythmy (rilmazafone)
  • 3.6.10 Rhythmy (rilmazafone)
  • 3.6.10 Valium (diazepam)
• 3.7 Rozerem Market Up-and-Coming

4 Insomnia Market Analysis by World Regions

• 4.1 US has the Highest Market Share for Insomnia Treatments
• 4.2 Europe as a Significant Market for Insomnia Treatments
• 4.3 The Japanese Market for Insomnia is Expanding

5 Market Developments for Narcolepsy, Shift Work Sleep Disorder, and Restless Legs Syndrome

• 5.1 Provigil Wins Label Extension
• 5.2 Adrafinil is a Isomer of Provigil
• 5.3 Ritalin/ Ritalin SR
• 5.4 Concerta is an Extension Version of Ritalin
• 5.5 Adderall as Stimulant
• 5.6 Xyrem for Cataplexy and Excessive Daytime Sleepiness
• 5.7 Recent FDA Activities for Restless Legs Syndrome

6 Products in Development for Sleep Disorders

• 6.1 FDA Approves Generic Ambien
• 6.2 Circadin a Prolonged-Release Melatonin
• 6.3 GHB analogue Generally Regarded as Safe
• 6.4 Clinical Trial Product List for Insomnia
• 6.5 Indiplon for Insomnia in Pre-Registration Stage
• 6.6 Caraco' s Prospect in Narcolepsy Market
• 6.7 Lundbeck Faces Setback in Insomnia Market
• 6.8 Phase III Trial Begins on Posidorm for Insomnia
• 6.9 Hope for Physiological Sleep with Almorexant
• 6.10 5HT2A Antagonist for Insomnia
• 6.11 Agonist at the Serotonin 5-HT1A Receptor
• 6.12 VEC-162 Future Contender for Rozerem
• 6.13 Zolpidem as Oral Spray
• 6.14 Cephalon Adds Nuvigil Alongside Provigil
• 6.15 Dopamine Patch for RLS
• 6.16 Transported Prodrug of Gabapentin

7 Recommendations for Ideal Pharmaceutical Treatment for Sleep Disorders

• 7.1 Firsthand Interview for Expert Opinion 1
  • 7.1.1 Prospect for Sleep Disorders Market
  • 7.1.2 Prospect for Generic Market
  • 7.1.3 Product Line Extension
  • 7.1.4 Prospect for Niche Market
  • 7.1.5 Future of Benzodiazepines Market
  • 7.1.6 Future of Controlled Drug Market
  • 7.1.7 Effect of Direct-to-Consumer Market
  • 7.1.8 Future of Non-Hypnotics Medications
  • 7.1.9 Future Medications for Sleep Apnoea
  • 7.1.10 Prospect for Hypnotics as OTCs
  • 7.1.12 Unmet Needs for Sleep Disorders Market
• 7.2 Firsthand Interview for Expert Opinion 2
  • 7.2.1 Drug Therapies for the Future
  • 7.2.2 Technological Advance in Sleep Disorders Treatment
  • 7.2.3 New Effective Sleep Medications
  • 7.2.4 Future of Sleep Disorders Market in the Developed Nations
  • 7.2.5 Unmet Needs for Sleep Disorders Treatment
  • 7.2.6 Favourable Medication for the Coming Decade
  • 7.2.7 Side-Effect Profile for Future Drug Development
  • 7.2.8 Sleep Disorders Market in Developing Nations

8 Market Force and Limitation of Sleep Disorders Market

• 8.1 Table for SWOT Analysis of Sleep Disorders Market
• 8.2 Market Analysis of Products Unapproved for Sleep Disorders by Regulatory Bodies and Niche Market
  • 8.2.1 Unapproved Insomnia Medications: Benadryl, Unisom, Tylenol PM, Nytol
  • 8.2.3 Purchase of Prescription Medications Online
• 8.3 Drug Safety Issues and Side-Effects of Drugs
  • 8.3.1 Hypnotics are not Without Side-Effects
  • 8.3.2 Labelling to include Potential Risks
  • 8.3.3 Rohypnol and Xyrem have Potential for Abuse
  • 8.4.4 Consumer Led Campaign
• 8.4 Unmet needs of Pharmaceutical Treatment for Sleep Disorders
• 8.5 Non-product Related Drivers and Restraints
  • 8.5.1 National Policies Recommendations
  • 8.5.2 National Policies Advising Prescription of Particular Drugs
  • 8.5.3 Agreed Guidelines
  • 8.5.4 Market Status Quo
• 8.6 Success of Direct-to-Consumer Advertising

9 Conclusions

• 9.1 Insomnia Market Will Show High Growth
• 9.2 Other Sleep Disorders of Interest
• 9.3 Life-Cycle Management
• 9.4 New Markets

Organisations mentioned in the report

• Abbott
• Actelion
• Alliance
• American Insomnia Association
• Andx
• Apotex
• Arena
• Astellas
• Avant
• Aventis
• Bayer
• Boehringer Ingelheim
• Caraco
• Carlsbad
• Cephalon
• Dr. Reddy' s
• Elan
• Eli Lilly
• Drug Enforcement Administration (DEA)
• European Patent Office
• FDA
• Genpharm
• GlaxoSmithKline
• Hoffman-Roche
• Hypnion
• Ipsen
• Johnson & Johnson
• King
• Lek
• Lundbeck
• Mallinckrodt
• Merck
• Mutual
• MHRA
• Mylan
• National Sleep Foundation
• NCSDR
• Neurim
• Neurocrine
• Neurogen
• NHLBI
• NICE
• NIH
• NovaDel
• Novartis
• Orphan
• Pfizer
• Pharmaceutical Researchers and Manufacturers of America (PhRMA)
• Questcor
• Ranbaxy
• Roche
• Rhone-Poulenc Rorer
• Roxane
• Royal Pharmaceutical Society of Great Britain (RPSGB)
• Sanofi-Aventis
• Schering-Plough
• Sepracor
• Shionogi
• Shire
• Skye
• Synthon
• Takeda
• Teva
• Tikvah
• UCB
• Valeant
• Vanda
• Watson
• Wyeth
• XenoPort